アクセス • お問い合わせ

|   Home   |   ご挨拶   |   メンバー   |   研究内容   |   業績   |   講義   |  大学院生募集　|  リンク  |

　 研究業績

2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009

-2021-

【原著論文】
  1. Shingo Oda, Yuka Hirabuki, Taiki Takeuchi, Takumi Kagawa, and Tsuyoshi Yokoi. Plasma miR-218a-5p as a biomarker for acute cholestatic liver injury in rats and investigation of its pathophysiological roles. J. Appl. Toxicol., in press. [Pubmed] NEW
  2. Kosuke Yoshida, Akira Yokoi, Mai Sugiyama, Shingo Oda, Kazuhisa Kitami, Satoshi Tamauchi, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Kaoru Niimi, Shiro Suzuki, Fumitaka Kikkawa, Tsuyoshi Yokoi, and Hiroaki Kajiyama. Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance. Oncogene, in press. [Pubmed] NEW
  3. Shingo Oda, Yuka Uchida, Michael D. Aleo, Petra H. Koza-Taylor, Yusuke Matsui, Masanori Hizue, Lisa D. Marroquin, Jessica Whritenour, Eri Uchida, and Tsuyoshi Yokoi. An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch. Toxicol., 95:149-168 (2021). [Pubmed] 

【総説・著書等】
  1. Shingo Oda and Tsuyoshi Yokoi. Recent progress in the use of microRNAs as biomarkers for drug-induced toxicities in contrast to traditional biomarkers: a comparative review. Drug Metab. Pharmacokinet., in press. [Pubmed] NEW
  2. Tsuyoshi Yokoi and Shingo Oda. Models of idiosyncratic drug-induced liver injury. Ann. Rev. Pharmacol. Toxicol., 61:247-268 (2021). [Pubmed] NEW

-2020-

【原著論文】  
  1. Ru Jia, Shingo Oda, and Tsuyoshi Yokoi. Pharmacological evidence for the involvement of ryanodine receptors in halothane-induced liver injury in mice. Toxicology, 443:152560 (2020). [Pubmed]
  2. Reo Kawata, Shingo Oda, Yoshihiro Koya, Hiroaki Kajiyama, and Tsuyoshi Yokoi. Macrophage-derived extracellular vesicles regulate concanavalin A-induced hepatitis by suppressing macrophage cytokine production. Toxicology, 443:152544 (2020). [Pubmed]
  3. Shingo Oda, Nanaka Miyazaki, Koichi Tsuneyama, and Tsuyoshi Yokoi. Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice. J. Toxicol. Sci., 45:493-502 (2020). [Pubmed]
  4. Reo Kawata, Takumi Kagawa, Yoshihiro Koya, Hiroaki Kajiyama, Shingo Oda, and Tsuyoshi Yokoi. Exploration of small RNA biomarkers for testicular injury in the serum exosomes of rats. Toxicology, 440:152490 (2020). [Pubmed] 

【総説・著書等】
  1. 横井毅. 薬物性肝障害評価研究の進歩. 日本薬理学雑誌, 155:323-328 (2020). [Journal]
  2. 織田進吾. 薬剤性肝障害動物モデルにおけるバイオマーカーとしての循環microRNA. 谷本学校 毒性質問箱, in press. [Journal]

-2019-

【原著論文】
  1. Kosuke Yoshida, Akira Yokoi, Takumi Kagawa, Shingo Oda, Satomi Hattori, Satoshi Tamauchi, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Fumi Utsumi, Kaoru Niimi, Shiro Suzuki, Kiyosumi Shibata, Hiroaki Kajiyama, Tsuyoshi Yokoi, and Fumitaka Kikkawa. Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. Carcinogenesis, 40:1435-1444 (2019). [Pubmed] 
  2. Ru Jia, Shingo Oda, Koichi Tsuneyama, Yuya Urano, and Tsuyoshi Yokoi. Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism. J. Appl. Toxicol., 39:1541-1556. [Pubmed] 
  3. Saki Gotoh-Saito, Takayuki Abe, Yoichi Furukawa, Shingo Oda, Tsuyoshi Yokoi, Moshe Finel, Masahiko Hatakeyama, Tatsuki Fukami, and Miki Nakajima. Characterization of human UGT2A3 expression using a prepared specific antibody against UGT2A3.  Drug Metab. Pharmacokinet., 34:280-286 (2019). [Pubmed]
  4. Reo Kawata and Tsuyoshi Yokoi. Analysis of a skeletal muscle injury and drug interactions in lovastatin and fenofibrate-coadministered dogs. Int. J. Toxicol., 38:192-201 (2019). [Pubmed]
  5. Fuhua Yang, Taiki Takeuchi, Koichi Tsuneyama, Tsuyoshi Yokoi and Shingo Oda. Experimental evidence of liver injury by BSEP-inhibiting drugs with a bile salt supplementation in rats. Toxicol. Sci., 170:95-108 (2019). [Pubmed]
  6. Katsuhito Watanabe, Shingo Oda, Akiko Matsubara, Sho Akai, and Tsuyoshi Yokoi. Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. Toxicol. Lett., 207:49-58 (2019). [Pubmed]
  7. Takumi Kagawa, Tomáš Zárybnický, Takanao Omi, Yuji Shirai, Shinya Toyokuni, Shingo Oda, and Tsuyoshi Yokoi. A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. Toxicology, 415:26-36 (2019). [Pubmed] 
  8. Akiko Matsubara, Shingo Oda, Ru Jia, and Tsuyoshi Yokoi. Acute kidney injury model established by systemic glutathione depletion in mice. J. Appl. Toxicol., 39:919-930 (2019). [Pubmed] 
  9. Sho Akai, Shingo Oda, and Tsuyoshi Yokoi. Strain and interindividual differences in lamotrigine-induced liver injury in mice. J. Appl. Toxicol., 39:451-460 (2019). [Pubmed].

-2018-

【原著論文】
  1. Yuya Urano, Shingo Oda, Koichi Tsuneyama, and Tsuyoshi Yokoi. Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. Chem. Biol. Interact., 296:185-197 (2018). [Pubmed] 
  2. Takumi Kagawa, Yuji Shirai, Shingo Oda, and Tsuyoshi Yokoi. Identification of specific microRNA biomarkers in early stages of hepatocellular injury, cholestasis, and steatosis in rats. Toxicol. Sci., 166:228-239 (2018). [Pubmed]
  3. Masaki Takeuchi, Shingo Oda, Koichi Tsuneyama, and Tsuyoshi Yokoi. Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early-phase biomarkers for SOS. Arch. Toxicol., 92:2947-2962 (2018). [Pubmed]
  4. Akiko Matsubara, Shingo Oda, Sho Akai, Koichi Tsuneyama, and Tsuyoshi Yokoi. Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. Toxiclol. Lett., 291:184-193 (2018). [Pubmed]
  5. Jieyu Xu, Shingo Oda, and Tsuyoshi Yokoi. Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. Toxicol. In Vitro, 48:286-301 (2018). [Pubmed]
  6. Shingo Oda, Masaki Takeuchi, Sho Akai, Yuji Shirai, Koichi Tsuneyama, and Tsuyoshi Yokoi. MicroRNA in rat liver sinusoidal endothelial cells and hepatocytes and application to circulating biomarkers that discern pathogenesis of liver injuries. Am. J. Pathol., 188:916-928 (2018). [Pubmed]
  7. Shohei Yamashita, Shingo Oda, Hideko Endo, Koichi Tsuneyama, and Tsuyoshi Yokoi. Neutrophil depletion protects against zomepirac-induced acute kidney injury in mice. Chem. Biol. Interact., 279:102-110 (2018). [Pubmed]
  8. Akira Nakajima, Hiroki Sato, Shingo Oda, and Tsuyoshi Yokoi. Fluoroquinolones and propionic acid derivatives induce inflammatory responses in vitro. Cell Biol. Toxicol., 34:65-77 (2018). [Pubmed]

【総説・著書等】
  1. Eita Sasaki and Tsuyoshi Yokoi. Role of cytochrome P450-mediated metabolism and involvement of reactive metabolite formations on antiepileptic drug-induced liver injuries. J. Toxicol. Sci., 43:75-87 (2018). [Pubmed]


 -2017-

【原著論文】
  1. Yu Yamaura, Naoyuki Tatsumi, Shingo Takagi, Shinsaku Tokumitsu, Tatsuki Fukami, Kazuto Tajiri, Masami Minemura, Tsuyoshi Yokoi, and Miki Nakajima. Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. Clin. Biochem., 50:1034-1039 (2017). [Pubmed] 
  2. Shingo Oda, Yukiko Kato, Masahiko Hatakeyama, Atsushi Iwamura, Tatsuki Fukami, Toshiyuki Kume, Tsuyoshi Yokoi, and Miki Nakajima. Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibody. Drug Metab. Dispos., 45:1027-1034 (2017). [Pubmed] 
  3. Sho Akai, Shingo Oda, and Tsuyoshi Yokoi. Establishment of a novel mouse model for pioglitazone-induced skeletal muscle injury. Toxicology, 382:1-9 (2017). [Pubmed]
  4. Yuji Shirai, Shingo Oda, Sayaka Makino, Koichi Tsuneyama, and Tsuyoshi Yokoi. Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis. Lab. Invest., 97:833-842 (2017). [Pubmed] 
  5. Shingo Oda, Yuji Shirai, Sho Akai, Akira Nakajima, Koichi Tsuneyama, and Tsuyoshi Yokoi. Toxicological role of an acyl glucuronide metabolite in diclofenac-induced acute liver injury in mice. J. Appl. Toxicol., 37:545-553 (2017). [Pubmed] 
  6. Takafumi Tomida, Hayao Okamura, Tsuyoshi Yokoi, and Yoshihiro Konno. A modified multiparametric assay using HepaRG cells for predicting the degree of drug-induced liver injury risk. J. Appl. Toxicol., 37:382-390 (2017). [Pubmed]

【総説・著書等】
  1. 横井 毅、織田進吾. 薬物代謝・薬物動態研究の最近の動向と展望 -医薬品開発研究を中心として-。化学と生物, 55:412-420 (2017).
  2. Atsushi Iwamura, Miki Nakajima, Shingo Oda, and Tsuyoshi Yokoi. Toxicological potential of acyl glucuronides and its assessment. Drug Metab. Pharmacokinet., 32:2-11 (2017). [Pubmed]
  3. 横井　毅. 薬剤性肝胆膵障害「図解 薬害副作用学 改訂2版」川西正祐、小野秀樹、賀川義之編、南山堂、282-291 (2017).

-2016-

【原著論文】
  1. Yasuaki Uematsu, Sho Akai, Tomoaki Tochitani, Shingo Oda, Toru Yamada and Tsuyoshi Yokoi. MicroRNA-mediated Th2 bias in methimazole-induced acute liver injury in mice. Toxicol. Appl. Pharmacol., 307:1-9 (2016). [Pubmed]
  2. Atsushi Iwamura, Katsuhito Watanabe, Sho Akai, Tsubasa Nishinosono, Koichi Tsuneyama, Shingo Oda, Toshiyuki Kume, and Tsuyoshi Yokoi. Zomepirac acyl glucuronide is responsible for zomepirac-induced acute kidney injury in mice. Drug Metab. Dispos., 44:888-896 (2016). [Pubmed] 
  3. Abhiruj Chiangsom, Somsong Lawanprasert, Rataya Luechapudiporn, Shingo Oda, Tsuyoshi Yokoi, Kornphimol Kulthong, and Rawiwan Maniratanachote. Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. Drug Metab. Pharmacokinet., 31: 210-217 (2016). [Pubmed]
  4. Shingo Oda, Kentaro Matsuo, Akira Nakajima, and Tsuyoshi Yokoi. A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. Toxicol. Lett., 241: 60-70 (2016). [Pubmed] 
  5. Akira Nakajima, Shingo Oda, and Tsuyoshi Yokoi. Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells. J. Appl. Toxicol., 36:1120-1128 (2016). [Pubmed]
  6. Eita Sasaki, Azumi Iida, Shingo Oda, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. Exp. Toxicol. Pathol., 68: 27-38 (2016). [Pubmed]
  7. Sho Akai, Yasuaki Uematsu, Koichi Tsuneyama, Shingo Oda, and Tsuyoshi Yokoi. Kupffer cell-mediated exacerbation of methimazole-induced acute liver injury in rats. J. Appl. Toxicol., 36: 702-715 (2016). [Pubmed] 
  8. Shohei Takai, Shingo Oda, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. J. Appl. Toxicol., 36: 35-47 (2016). [Pubmed]

【総説・著書等】
  1. Ryoichi Fujiwara, Tsuyoshi Yokoi, and Miki Nakajima. Structure and protein-protein interactions of human UDP-glucuronosyltansferases. Front. Pharmacol., 7: 388 (2016). [Pubmed]
  2. 織田進吾, 横井　毅. いまさら聞けない薬物動態Q＆A: 薬剤師が知っておきたい抱合酵素とその基質について教えてください 月刊薬事, 58: 685-690 (2016). [web]


-2015-

【原著論文】
  1. Atsushi Iwamura, Masahito Ito, Hideaki Mitsui, Jun Hasegawa, Keigo Kosaka, Ichiro Kino, Minoru Tsuda, Miki Nakajima, Tsuyoshi Yokoi, and Toshiyuki Kume. Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. Toxicol. In Vitro, 30: 241-249 (2015). [Pubmed]
  2. Akira Nakajima, Yuki Aoyama, Eun-Joo Shin, Yunsung Nam, Hyoung-Chun Kim, Taku Nagai, Akihito Yokosuka, Yoshihiro Mimaki, Tsuyoshi Yokoi, Yasushi Ohizumi, and Kiyofumi Yamada. Nobiletin, a citrus flavonoid, improves cognitive impairment and resuces soluble Ab levels in a triple transgenic mouse model of Alzheimer’s disease (3XTg-AD). Behav. Brain. Res., 289: 69-77 (2015). [Pubmed]
  3. Takafumi Tomida, Hayao Okamura, Masahiro Satsukawa, Tsuyoshi Yokoi, Yoshihiro Konno. Mutipaprmetric assay using HepaRG cells for predicting drug-induced liver injury. Toxicol. Lett., 236: 16-24 (2015). [Pubmed]
  4. Azumi Iida, Eita Sasaki, Azusa Yano, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Carbamazepine-induced liver injury requires CYP3A-mediated metabolism and glutathione depletion in rats. Drug Metab. Dispos., 43: 958-968 (2015). [Pubmed]
  5. Shingo Oda, Ryoichi Fujiwara, Yuki Kutsuno, Tatsuki Fukami, Tomoo Itoh, Tsuyoshi Yokoi, and Miki Nakajima. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. Drug Metab. Dispos., 43: 812-818 (2015). [Pubmed] [DMD Highlight]
  6. Masataka Nakano, Yasunari Fukushima, Shin-ichi Yokota, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, Tsuyoshi Yokoi, and Miki Nakajima. CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126*. Drug Metab. Dispos., 43: 703-712 (2015). [Pubmed] [DMD Highlight]
  7. Yun-Ping Lim, Ching-Hao Chen, Wei-Cheng Chen, Shih-Yu Chang, Dong-Zong Hung, Jih-Jung Chen, Lei Wan, Wei-Chih Ma, Yu-Hsien Lin, Cing-Yu Chen, Tsuyoshi Yokoi, Miki Nakajima and Chao-Jung Chen. Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity. Arch. Toxicol., 89: 57-72 (2015). [Pubmed]
  8. Shohei Takai, Satonori Higuchi, Azusa Yano, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice. J. Appl. Toxicol., 35: 142–151 (2015). [Pubmed]

【総説・著書等】
  1. Shingo Oda and Tsuyoshi Yokoi. Establishment of Animal Models of Drug-induced Liver Injury and Analysis of Possible Mechanisms. Yakugaku Zasshi,  135: 579-588 (2015). [Pubmed]
  2. Shingo Oda*, Tatsuki Fukami*, Tsuyoshi Yokoi, and Miki Nakajima (*Equally contributed). A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab. Pharmacokinet., 30: 30-51 (2015). [Pubmed]

-2014-

【原著論文】
  1. Yusuke Ito, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima. An orphan esterase ABHD10 mudolates probenecid acyl glucuronidation in human liver. Drug Metab. Dispos., 42: 2109-2116 (2014). [Pubmed]
  2. Eita Sasaki, Atsushi Iwamura, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, Toshiyuki Kume and Tsuyoshi Yokoi. Role of P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury. Toxicol. Lett., 232: 79-88 (2014). [Pubmed]
  3. Yun-Ping Lim, Wei-Cheng Chen, Ching-Hao Cheng, Wei-Chih Ma, Yu-Hsien Lin, Cing-Yu Chen, Dong-Zong Hung, Jih-Jung Chen, Tsuyoshi Yokoi, Miki Nakajima, and Chao-Jung Chen. Inhibition of cytochrome P450 2C9 expression and activity in vitro by allyl isothiocyanate. Planta Med., 80: 1097-1106 (2014). [Pubmed]
  4. Mark J. Kurth, Tsuyoshi Yokoi, and M. Eric Gershwin. Halothane-induced hepatitis: Paradigm or paradox for drug-induced liver injury. Hepatology, 60: 1473-1475 (2014). [Pubmed]
  5. Yu Yamaura, Miki Nakajima, Naoyuki Tatsumi, Shingo Takagi, Tatsuki Fukami, Koichi Tsuneyama, and Tsuyoshi Yokoi. Changes in the expression of miRNAs at the pericentral and periportal regions of the rat liver in response to hepatocellular injury: Comparison with the changes in the expression of plasma miRNAs. Toxicology, 322: 89-98 (2014). [Pubmed]
  6. Yuki Oda, Miki Nakajima, Koichi Tsuneyama, Masataka Takamiya, Yasuhiro Aoki, Tatsuki Fukami, and Tsuyoshi Yokoi. Retinoid X receptor alpha in human liver is regulated by miR-34a. Biochem. Pharmacol., 90: 179-187 (2014). [Pubmed]
  7. Mai Shimizu, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab. Dispos., 42: 1103-1109 (2014). [Pubmed]
  8. Azusa Yano, Shingo Oda, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicol. Lett., 228: 13-24 (2014). [Pubmed]
  9. Seng Chuan Tang, Rolf W. Sparidans, Ka Lei Cheung, Tatsuki Fukami, Selvi Durmus, Els Wagenaar, Tsuyoshi Yokoi, Bart J. M. van Vlijmen, Jos H. Beijnen, and Alfred H. Schinkel. P-glycoprotein, CYP3A and plasma carboxylesterase determine brain and blood disposition of the mTOR inhibitor everolimus (Afinitor) in mice. Clin. Cancer Res., 20: 3133-3145 (2014). [Pubmed]
  10. Shinya Endo, Azusa Yano, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Involvement of miRNAs in the early phase of halothane-induced liver injury. Toxicology, 319: 75-84 (2014). [Pubmed]
  11. Kei Takahashi, Naoyuki Tatsumi, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima. Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab. Pharmacokinet., 29:333-340 (2014). [Pubmed] DMPK Editors' Award for the Most Excellent Article in 2014
  12. Mai Shimizu, Tatsuki Fukami, Yusuke Ito, Takaya Kurokawa, Motoki Kariya, Miki Nakajima, and Tsuyoshi Yokoi. Indiplon is hydrolyzed by arylacetamide deacetylase in human liver. Drug Metab. Dispos., 42: 751-758 (2014). [Pubmed]
  13. Shingo Oda, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima. Epigenetic regulation of the tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10. Biochem. Pharmacol., 87: 660-667 (2014). [Pubmed]
  14. Shuichi Kuno, Fuminori Sakurai, Kahori Shimizu, Naoya Matsumura, Soonih Kim, Hitoshi Watanabe, Katsuhisa Tashiro, Masashi Tachibana, Tsuyoshi Yokoi, and Hiroyuki Mizuguchi. Development of mice exhibiting hepatic microsomal activity of human CYP3A4 comparable to that in human liver microsomes by intravenous administration of an adenovirus vector expressing human CYP3A4. Drug Metab. Pharmacokinet., 29: 296-304 (2014). [Pubmed]
  15. Kentaro Matsuo, Eita Sasaki, Satorori Higuchi, Shohei Takai, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injury. Toxicol. Lett., 224: 215-224 (2014). [Pubmed]
  16. Kyotaka Muta, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity. Biochem. Pharmacol., 87: 352-359 (2014). [Pubmed]
  17. Taishi Miyashita, Kento Kimura, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs. Drug Metab. Dispos., 42: 1-8 (2014). [Pubmed]
  18. Kei Takahashi, Yuki Oda, Yasuyuki Toyoda, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima. Regulation of cytochrome b5 expression by miR-223 in human liver; effects on cytochrome P450 activities. Pharm. Res., 31: 780-794 (2014). [Pubmed]

【総説・著書等】
  1. 織田進吾, 横井　毅. 薬物性肝障害における免疫・炎症因子の関与. 日本皮膚アレルギー・接触皮膚炎学会雑誌, 8: 239-248 (2014).[web]
  2. 横井　毅．肝障害とバイオマーカーとしてのmiRNA. 谷本学校 毒性質問箱, 16:56-67 (2014).[web]
  3. 横井　毅．薬物代謝と肝障害：薬物代謝と免疫・炎症を考慮した薬物性肝障害の理解と展望. 日本薬理学雑誌, 144: 22-27 (2014). [Pubmed]
  4. 横井　毅．薬物代謝と肝障害. 月刊薬事 56: 21-25(2014).[web]
  5. Miki Nakajima and Tsuyoshi Yokoi. MicroRNA-Regulation of P450 and Pharmacogenetics. Sandosh Padmanabhan Ed. Handbook Pharmacogenomics and Stratified Medicines, Elsevier, Watham, pp.385-401 (2014).[web]


-2013-

【原著論文】
  1. Eita Sasaki, Kentaro Matsuo, Azumi Iida, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism. Toxicol. Sci., 136:250-263 (2013). [Pubmed]
  2. Kei Takahashi, Shin-ichi Yokota, Naoyuki Tatsumi, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima. Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicol. Appl. Pharmacol., 272: 154-160 (2013). [Pubmed]
  3. Yukiko Kato, Takeshi Izukawa, Shingo Oda, Tatsuki Fukami, Moshe Finel, Tsuyoshi Yokoi, and Miki Nakajima. Human UGT2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab. Dispos., 41: 1389-1397 (2013). [Pubmed]
  4. Ryota Higuchi, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Prilocaine- and lidocaine-induced methemoglobinemia is caused by human carboxylesterase-, CYP2E1-, and CYP3A4-mediated metabolic activation. Drug Metab. Dispos., 41: 1220-1230 (2013). [Pubmed]
  5. Shingo Oda, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima. Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney. Drug Metab. Dispos., 41: 1738-1743 (2013). [Pubmed]
  6. Ching Ho Poon, Tsz Yan Wong, Yanfei Wang, Yuki Tsuchiya, Miki Nakajima, Tsuyoshi Yokoi, and Lai K. Leung. The citrus flavonoids naringenin suppresses CYP1B1 transactivation through antagonising xenobiotic-responsive element binding. Br. J. Nutr., 109: 1598-1605 (2013). [Pubmed]
  7. Makoto Kataoka, Yuki Terashima, Katsuhiko Miuno, Yoshie Masaoka, Shinji Saluma, Tsuyoshi Yokoi, and Shinji Yamashita. Establishment of MDCKII cell monolayer with metabolic activity by CYP3A4 transduced with recombinant adnovirus. Drug Metab. Pharmacokinet., 28: 125-131 (2013). [Pubmed]

 　【総説・著書等】
  1. Tsuyoshi  Yokoi. A new era in the study of individual differences in drug metabolism and pharmacokinetics. Drug Metab. Pharmacokinet., 28: 1-2 (2013). [Pubmed]
  2. Tsuyoshi Yokoi and Miki Nakajima. MicroRNAs as mediators of drug toxicity. Ann. Rev. Pharmacol. Toxicol., 53: 377-400 (2013). [Pubmed]
  3. 横井　毅．体内動態と薬物相互作用の基礎と応用-食品成分への展開-．食品加工技術 33: 7-13(2013).
  4. 横井　毅. 薬物代謝反応・代謝酵素の多様性と薬物相互作用の予測 p198-204. 「In vitro毒性・動態評価の最前線」小島肇監修、シーエムシー出版 (2013).


-2012-

　【原著論文】
  1. Yuki Kobayashi, Tatsuki Fukami, Ryota Higuchi, Miki Nakajima, and Tsuyoshi Yokoi. Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Biochem. Pharmacol., 84: 1196-1206 (2012). [Pubmed]
  2. Masakazu Kakuni, Mayu Morita, Kentaro Matsuo, Yumiko Katoh, Miki Nakajima, Chise Tateno, and Tsuyoshi Yokoi. Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol. Lett., 214: 9-18 (2012). [Pubmed]
  3. Satonori Higuchi, Azusa Yano, Shohei Takai, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol. Sci., 130: 4-16 (2012). [Pubmed]
  4. Taishi Miyashita, Yasuyuki Toyoda, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. J. Toxicol. Sci., 37: 931-942 (2012). [Pubmed]
  5. Yukitaka Yoshikawa, Taishi Miyashita, Satorori Higuchi, Koichi Tsuneyama, Shinya Endo, Yasuyuki Toyoda, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. Toxcol. Appl. Pharmacol., 264: 42-50 (2012). [Pubmed]
  6. Shingo Oda, Miki Nakajima, Masahiko Hatakeyama, Tatsuki Fukami, and Tsuyoshi Yokoi. Preparation of a specific monoclonal antibody against human UGT1A9 and evaluation of UGT1A9 protein levels in human tissues. Drug Metab. Dispos., 40: 1620-1627 (2012). [Pubmed]
  7. Shinya Endo, Yasuyuki Toyoda, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs. Drug Metab. Pharmacokinet., 27: 621-630 (2012). [Pubmed]
  8. Yuki Kobayashi, Tatsuki Fukami, Mai Shimizu, Miki Nakajima, and Tsuyoshi Yokoi. Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Drug Metab. Dispos., 40: 1080-1084 (2012). [Pubmed]
  9. Mai Shimizu, Tatsuki Fukami, Yuki Kobayashi, Masataka Takamiya, Yoshihiro Aoki, Miki Nakajima and Tsuyoshi Yokoi. A novel polymorphic allele of human arylacetamide deacetylase leads to diminished enzyme activity. Drug Metab. Dispos., 40: 1183-1190 (2012). [Pubmed]
  10. Kornphimol Kulthong, Rawiwan Maniratanachote, Yuki Kobayashi, Tatsuki Fukami and Tsuyoshi Yokoi. Effects of silver nanoparticles on hepatic cytochrome P450 enzyme activity. Xenobiotica, 42: 854-862 (2012). [Pubmed]
  11. Yuki Oda, Miki Nakajima, Takuya Mohri, Masataka Takamiya, Yasuhiro Aoki, Tatsuki Fukami, and Tsuyoshi Yokoi. Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. Toxcol. Appl. Pharmacol., 260: 222-231 (2012). [Pubmed]
  12. Atsushi Iwamura, Tatsuki Fukami, Ryota Higuchi, Miki Nakajima, and Tsuyoshi Yokoi. Human a/b hydrolase domain containing 10 (ABHD10) is a responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. J. Biol. Chem., 287: 9240-9249 (2012). [Pubmed]
  13. Azusa Yano, Satonori Higuchi, Koichi Tsuneyama, Tasuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Involvement of immune-related factors in diclofenac-induced acute liver in mice. Toxicology, 293: 107-114 (2012). [Pubmed]
  14. Theerada Taesotikul, Miki Nakajima, Wichittra Tassaneeyakul, and Tsuyoshi Yokoi. Effects of Phyllanthus amarus extract on the pharmacokinetics of midazolam and cytochrome P450 activities in rats. Xenobiotica., 42: 641-648 (2012). [Pubmed]
  15. Masanori Kobayashi, Satorori Higuchi, Mika Ide, Satomi Nishikawa, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Th2 cytokines-mediated methimazole-induced liver injury in mice. J. Appl. Toxicol., 32: 823-833 (2012). [Pubmed]
  16. Yuki Kobayashi, Tatsuki Fukami, Akinori Nakajima, Akinobu Watanabe, Miki Nakajima, and Tsuyoshi Yokoi. Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab. Dispos., 40: 671-679 (2012). [Pubmed]
  17. Yu Yamaura, Miki Nakajima, Shingo Takagi, Tatsuki Fukami, Koichi Tsuneyama, and Tsuyoshi Yokoi. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS One, 7: e30250 (2012). [Pubmed]
  18. Yasuyuki Toyoda, Shinya Endo, Koichi Tsuneyama, Taishi Miyashita, Azusa Yano, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Mechanism of exacerbative effect of progesterone on drug-induced liver injury. Toxicol. Sci., 126: 16-27 (2012). [Pubmed]
  19. Yukiko Kato, Miki Nakajima, Shingo Oda, Tasuki Fukami, and Tsuyoshi Yokoi. Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contributions. Drug Metab. Dispos., 40: 240-248 (2012). [Pubmed]
  20. Satonori Higuchi, Masanori Kobayashi, Azusa Yano, Koichi Tsuneyama, Tastuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. J. Appl. Toxicol., 32: 815-822 (2012). [Pubmed]

【総説・著書等】
  1. Tatsuki Fukami and Tsuyoshi Yokoi. The Emerging role of human esterases. Drug Metab. Pharmacokinet., 27: 466-477 (2012). [Pubmed]


-2011-

【原著論文】
  1. Shingo Oda, Miki Nakajima, Yasuyuki Toyoda, Tatsuki Fukami, and Tsuyoshi Yokoi. Progesterone receptor membrane component 1 modulates human cytochrome P450 activities in an isoform-dependent manner. Drug Metab. Dispos., 39: 2057-2065 (2011). [Pubmed]
  2. Akinori Nakajima, Tatsuki Fukami, Yuki Kobayashi, Akinobu Watanabe, Miki Nakajima, and Tsuyoshi Yokoi. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem. Pharmacol., 82: 1747-1756 (2011). [Pubmed]
  3. Katsuhiko Kida, Miki Nakajima, Takuya Mohri, Yuki Oda, Shingo Takagi, Tasuki Fukami, and Tsuyoshi Yokoi. Peroxisome proliferator-activator receptor a is regulated by miR-21 and miR-27b in human liver. Pharm. Res., 28: 2467-2476 (2011). [Pubmed]
  4. Hiroko Hosomi, Tatsuki Fukami, Atsushi Iwamura, Miki Nakajima, and Tsuyoshi Yokoi. Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab. Dispos., 39: 1388-1395 (2011). [Pubmed]
  5. Tomomi Hioki, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. Drug Metab. Dispos., 39: 1345-1352 (2011). [Pubmed]
  6. Toru Usui, Takanori Hashizume, Takashi Katsumata, Tsuyoshi Yokoi, and Setsuko Komuro. In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug Metab. Dispos., 39: 1303-1310 (2011). [Pubmed]
  7. Yasuyuki Toyoda, Taishi Miyashita, Shinya Endo, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Estradiol and progesterone modulate halothane-induced liver injury in mice. Toxicol. Lett., 204: 17-24 (2011). [Pubmed]
  8. Atsushi Iwamura, Tatsuki Fukami, Hiroko Hosomi, Miki Nakajima, and Tsuyoshi Yokoi. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab. Dispos., 39: 838-846 (2011). [Pubmed]
  9. Yuko Abe, Ryoichi Fujiwara, Shingo Oda, and Tsuyoshi Yokoi, and Miki Nakajima. Interpretation for the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo. Drug Metab. Pharmacokinet., 26: 256-265 (2011). [Pubmed]
  10. Satonori Higuchi, Masanori Kobayashi, Yukitaka Yoshikawa, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. IL-4 mediated dicloxacillin-induced liver injury in mice. Toxicol. Lett., 200: 139-145 (2011). [Pubmed]
  11. Toshihisa Koga, Ryoichi Fujiwara, Miki Nakajima, and Tsuyoshi Yokoi. Toxicological evaluation of acyl glucuronides of NSAIDs using HEK293 cells stably expressing human UGT and human hepatocytes. Drug Metab. Dispos., 39: 54-60 (2011). [Pubmed]
  12. Shin-ichi Yokota, Eriko Higashi, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima. Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem. Pharmacol., 81: 289-294 (2011). [Pubmed]
  13. Katsuhiko Mizuno, Yasuyuki Toyoda, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. Arch. Toxicol., 85: 199-207 (2011). [Pubmed]

【総説・著書等】
  1. Tsuyoshi Yokoi and Miki Nakajima. Toxicological implications of modulation of gene expression by microRNAs. Toxicol. Sci., 123: 1-14 (2011). [Pubmed]
  2. Tsuyoshi Yokoi. Current topics in drug metabolism and drug toxicity. Drug Metab. Pharmacokinet., 26: 1-2 (2011). [Pubmed]
  3. Miki Nakajima and Tsuyoshi Yokoi. MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. Pharmacol. Ther., 131: 330-337 (2011). [Pubmed]
  4. 横井　毅. 第II相代謝の評価と創薬 p224-231.「医薬品開発に必要なストラテジーと各種試験法」日本薬理学会編 (2011).

-2010-

【原著論文】
  1. Akinobu Watanabe, Tatsuki Fukami, Shiori Takahashi, Nao Nakagawa, Miki Nakajima, and Tsuyoshi Yokoi. Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. Drug Metab. Dispos., 38: 1532-1537 (2010). [Pubmed]
  2. Masanori Kobayashi, Satorori Higuchi, Katsuhiko Mizuno, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Interleukin-17 is involved in a-naphthylisothiocyanate-induced liver injury in mice. Toxicology, 275: 50-57 (2010). [Pubmed]
  3. Tatsuki Fukami, Miki Nakajima, Isao Matsumoto, Yoh Zen, Makoto Oda, and Tsuyoshi Yokoi. Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Sci., 101: 1024-1028 (2010). [Pubmed]
  4. Tatsuki Fukami, Shiori Takahashi, Nao Nakagawa, Taiga Maruichi, Miki Nakajima, and Tsuyoshi Yokoi. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab. Dispos., 38: 2173-2178 (2010). [Pubmed]
  5. Katsuhiko Mizuno, Tatsuki Fukami, Yasuyuki Toyoda, Miki Nakajima, and Tsuyoshi Yokoi. Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway. Life Sci., 87: 537-544 (2010). [Pubmed]
  6. Roger S Holmes, Matthew Wright, Stanley JF Laulederkind, Laura A Cox, Masakiyo Hosokawa, Teruko Imai, Shun Ishibashi, Richard Lehner Masao Miyazaki, Everett J Perkins, Phillip M Potter, Matthew Redinbo, Jacques Robert, Tetsuo Satoh, Tetsuro Yamashita, Bingfang Yan, Tsuyoshi Yokoi, Rudolf Zechner, and Lois Maltais. Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse and rat genes and proteins. Mammalian Genome, 21: 427-441 (2010). [Pubmed]
  7. Shingo Takagi, Miki Nakajima, Katsuhiko Kida, Yu Yamaura, Tatsuki Fukami, and Tsuyoshi Yokoi. MicroRNAs regulate human hepatocytes nuclear factor 4a modulating the expression of metabolic enzymes and cell cycle. J. Biol. Chem., 285: 4415-4422 (2010). [Pubmed]
  8. Hiroko Hosomi, Sho Akai, Keiichi Minami, Yukitaka Yoshikawa, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. An in vivo drug-induced hepatotoxicity screeing system using CYP3A4-expressing and g-glutamylcysteine synthetase knockdown cells. Toxicol. in Vitro, 24: 1032-1038 (2010). [Pubmed]
  9. Miki Nakajima, Toshihisa Koga, Haruko Sakai, Hiroyuki Yamanaka, Ryoichi Fujiwara, and Tsuyoshi Yokoi. N-Glycosylation plays a role in protein folding to human UGT1A9. Biochem. Pharmacol., 79: 1165-1172 (2010). [Pubmed]
  10. Takuya Mohri, Miki Nakajima, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, and Tsuyoshi Yokoi. Human CYP2E1 is regulated by miR-378. Biochem. Pharmacol., 79: 1045-1052 (2010). [Pubmed]
  11. Taiga Maruichi, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). Biochem. Pharmacol., 79: 288-295 (2010). [Pubmed]
  12. Ryoichi Fujiwara, Miki Nakajima, Shingo Oda, Hiroyuki Yamanaka, Shin-ichi Ikushiro, Toshiyuki Sakaki, and Tsuyoshi Yokoi. Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. J. Pharm. Sci., 99: 442-454 (2010). [Pubmed]

【総説・著書等】
  1. 横井　毅. 薬物動態関連遺伝子の多型と薬物相互作用. 臨床検査 54:1107-1113 (2010).
  2. 横井　毅. 薬物代謝異常と小胞体　p235-250. 「生物薬科学実験講座５、細胞の構造とオルガネラ」大熊勝治、中西義信編集、廣川書店 (2010).
  3. 横井　毅. 薬物代謝に関与する酵素とその反応機構 p43-68、 薬物代謝と毒性発現 p182-192.「薬物代謝学　医療薬学・医薬品開発の基礎として第３版」加藤隆一、山添　康、横井　毅編、 東京化学同人 (2010).
  4. Tsuyoshi Yokoi.  Troglitazone p419-435. ｢Adverse Drug Reactions｣ Jack Uetrecht Ed. in Handbook of Expreimental Pharmacology 196, Springer-Verlag, Berlin (2010).

-2009-

【原著論文】
  1. Nao Nakagawa, Miki Katoh, Yuko Yoshioka, Miki Nakajima, and Tsuyoshi Yokoi. Inhibitory effects of Kampo medicine on human UGT2B7 activity. Drug Metab. Pharmacokinet., 24: 490-499 (2009). [Pubmed]
  2. Yukitaka Yoshikawa, Mayu Morita, Hiroko Hosomi, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Knockdown of superoxide dismutase-2 enhances acetaminophen-induced hepatotoxicity in rat. Toxicology, 264: 89-95 (2009). [Pubmed]
  3. Eisuke Kobayashi, Masanori Kobayashi, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci., 111: 302-310 (2009). [Pubmed]
  4. Sayaka Komagata, Miki Nakajima, Shingo Takagi, Takuya Mohri and Tsuyoshi Yokoi. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol., 76: 702-709 (2009). [Pubmed]
  5. Yukitaka Yoshikawa, Hiroko Hosomi, Tatsuki Fukami, Miki Nakajima and Tsuyoshi Yokoi. Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. Toxicol. in Vitro, 23: 1179-1187 (2009). [Pubmed]
  6. Mayu Morita, Sho Akai, Hiroko Hosomi, Koichi Tsuneyama, Miki Nakajima, and Tsuyoshi Yokoi. Drug-induced hepatotoxicity test using g-glutamylcysteine synthetase knockdown rat. Toxicol. Lett., 189: 159-165 (2009). [Pubmed]
  7. Takeshi Izukawa, Miki Nakajima, Ryoichi Fujiwara, Hiroyuki Yamanaka, Tatsuki Fukami, Masataka Takamiya, Yasuhiro Aoki, Shin-ichi Ikushiro, Toshiyuki Sakaki and Tsuyoshi Yokoi. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab. Dispos., 37: 1759-1768 (2009). [Pubmed]
  8. Akinobu Watanabe, Tatsuki Fukami, Mikik Nakajima, Masataka Takamiya, Yasuhiro Aoki and Tsuyoshi Yokoi. Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. Drug Metab. Dispos., 37: 1513-1520 (2009). [Pubmed]
  9. Takuya Mohri, Miki Nakajima, Shingo Takagi and Tsuyoshi Yokoi. MicroRNA regulates human vitamin D receptor. Int J Cancer, 125: 1328-1333 (2009). [Pubmed]
  10. Marjo Volotinen, Jukka Mäenpää, Esko Kankuri, Olli Oksala, Olavi Perkonen, Miki Nakajima, Tsuyoshi Yokoi, and Jukka Hakkola. Expression of cytochrome P450 (CYP) enzymes in human non-pigmented ciliary epithelial cells; induction of CYP1B1 expression by TCDD. Invest. Ophth. Vis. Sci., 50: 3099-3105 (2009). [Pubmed]
  11. Shiori Takahashi, Miki Katoh, Takashi Saitoh, Miki Nakajima, and Tsuyoshi Yokoi. Different inhibitory effects in rat and human carboxylesterases. Drug Metab. Dispos., 37: 956-961 (2009). [Pubmed]
  12. Kenji Ishihara, Naruo Katsutani, Naoki Asai, Akira Inomata, Yuji Uemura, Akiyoshi Suganuma, Kohei Sawada, Tsuyoshi Yokoi, and Toyohiko Aoki. Identification of urinary biomarkers useful for distinguishing a difference in mechanism of toxicology in rat model of cholestasis. Basic Clin Pharmacol Toxicol., 105: 156-166 (2009). [Pubmed]
  13. Ryoichi Fujiwara, Miki Nakajima, Tetsunori Yamamoto, Hidemi Nagao, and Tsuyoshi Yokoi. In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9. Drug Metab. Pharmacokinet., 24: 235-244 (2009). [Pubmed] DMPK Best Article Award 2010
  14. Miki Katoh, Yuko Yoshioka, Nao Nakawawa, and Tsuyoshi Yokoi: Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity. Drug Metab. Pharmacokinet., 24: 226-234 (2009). [Pubmed]
  15. Katsuhiko Mizuno, Miki Katoh, Hirotoshi Okumura, Nao Nakagawa, Toru Negishi, Takanori Hashizume, Miki Nakajima, and Tsuyoshi Yokoi. Metabolic activation of benzodiazepine by CYP3A4. Drug Metab. Dispos., 37: 345-351 (2009). [Pubmed]
  16. Ryoichi Fujiwara, Miki Nakajima, Hiroyuki Yamanaka, and Tsuyoshi Yokoi. Key amino acid residues responsible for the differences in substrate specificity of human UDP-glucuronosyltransferase (UGT) 1A9 and UGT1A8. Drug Metab. Dispos., 37: 41-46 (2009). [Pubmed]

【総説・著書等】
  1. Tsuyoshi Yokoi. Essentials for starting a pediatric clinical study(1): Pharmacokinetics in children. J. Tox. Sci., 34:S307-312 (2009). [Pubmed]
  2. 横井　毅. 薬物動態と医薬品の薬効・副作用:代謝を中心として．治療学 43:1262-1266 (2009).
  3. 横井　毅. 第II相代謝の評価と創薬：化合物から医薬品にするために必要な薬物動態試験．日本薬理学雑誌 134:334-337 (2009).　
  4. 横井　毅. 薬物動態関連遺伝子の多型と薬物相互作用．DNA多型17:6-10(2009).
  5. 横井　毅. 薬物の作用, 薬物動態の基本 p9-20.「医薬品トキシコロジー 改訂第４版」佐藤哲男、仮家公夫、北田光一編、南江堂 (2009).
  6. 横井　毅. 薬物療法の個人差と薬物代謝酵素の遺伝子多型 p43-47. ひらかれた小児リウマチ治療、セカンド出版(2009).
  7. 横井　毅. 毒科学とゲノムサイエンス・トキシコゲノミクス p56-60「標準医療薬学　薬理学」辻本豪三、小池勝夫編、医学書院(2009).

Last updated: February 13, 2021
Copyright © 2014 Toxicogenomics, Nagoya University Graduate School of Medicine. All Rights Reserved.